|
English
|
正體中文
|
简体中文
|
總筆數 :2856600
|
|
造訪人次 :
53473713
線上人數 :
830
教育部委託研究計畫 計畫執行:國立臺灣大學圖書館
|
|
|
"alam j"的相關文件
顯示項目 1-5 / 5 (共1頁)
1
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2023-10-30 |
Extended-spectrum beta-lactamases (ESBL): Challenges and opportunities
|
Husna, A;Rahman, MM;Badruzzaman, ATM;Sikder, MH;Islam, MR;Rahman, MT;Alam, J;Ashour, HM |
| 臺大學術典藏 |
2020-05-25T06:51:44Z |
Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study
|
Im S.-A;Sohn J;Tripathy D;Chow L;Lee K.S;Jung K.H;Babu G;Im Y.-H;El Saghir N;Liu M.-C;Diaz-Padilla I;Alam J;Kong O;Miller M;Yen-Shen Lu; Im S.-A; Sohn J; Tripathy D; Chow L; Lee K.S; Jung K.H; Babu G; Im Y.-H; El Saghir N; Liu M.-C; Diaz-Padilla I; Alam J; Kong O; Miller M; YEN-SHEN LU |
| 臺大學術典藏 |
2020-05-25T06:51:44Z |
Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study
|
Im S.-A;Sohn J;Tripathy D;Chow L;Lee K.S;Jung K.H;Babu G;Im Y.-H;El Saghir N;Liu M.-C;Diaz-Padilla I;Alam J;Kong O;Miller M;Yen-Shen Lu; Im S.-A; Sohn J; Tripathy D; Chow L; Lee K.S; Jung K.H; Babu G; Im Y.-H; El Saghir N; Liu M.-C; Diaz-Padilla I; Alam J; Kong O; Miller M; YEN-SHEN LU |
| 臺大學術典藏 |
2020-05-25T06:51:44Z |
Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis
|
Bardia A;Campos-Gomez S;Hurvitz S.A;Yen-Shen Lu;Im S.-A;Franke F;Chow L;Wheatley-Price P;Melo Cruz F;Alam J;Kong O;Diaz-Padilla I;Miller M;Tripathy D.; Bardia A; Campos-Gomez S; Hurvitz S.A; YEN-SHEN LU; Im S.-A; Franke F; Chow L; Wheatley-Price P; Melo Cruz F; Alam J; Kong O; Diaz-Padilla I; Miller M; Tripathy D. |
| 臺大學術典藏 |
2020-05-25T06:51:44Z |
Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis
|
Bardia A;Campos-Gomez S;Hurvitz S.A;Yen-Shen Lu;Im S.-A;Franke F;Chow L;Wheatley-Price P;Melo Cruz F;Alam J;Kong O;Diaz-Padilla I;Miller M;Tripathy D.; Bardia A; Campos-Gomez S; Hurvitz S.A; YEN-SHEN LU; Im S.-A; Franke F; Chow L; Wheatley-Price P; Melo Cruz F; Alam J; Kong O; Diaz-Padilla I; Miller M; Tripathy D. |
顯示項目 1-5 / 5 (共1頁)
1
每頁顯示[10|25|50]項目
|
